Physician profile
Caleb J Scheckel
NPI 1447606348
$159,302.88
in general payments reported to CMS, 2019-2025
34 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.02 · 2023: $6,101 · 2024: $46K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Consulting Fee: $56K · Travel and Lodging: $8,550 · Food and Beverage: $4,063 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Education: $32.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,707.92 |
| Consulting Fee | $56,168.75 |
| Travel and Lodging | $8,550.32 |
| Food and Beverage | $4,063.41 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Education | $32.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51,548.26 | 2023-2025 | Calquence, Lumoxiti, Enhertu |
| Pfizer INC. | $32,980.63 | 2024-2025 | |
| Beone Medicines USA, INC. | $30,010.11 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $21,256.94 | 2023-2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $13,648.14 | 2023-2025 | Opdivo |
| Abbvie INC. | $3,315.67 | 2024 | |
| Novartis Pharmaceuticals Corporation | $2,198.28 | 2024-2025 | |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $1,052.79 | 2023-2025 | Fotivda |
| Adc Therapeutics America, INC. | $260.99 | 2023-2025 | |
| Janssen Biotech, INC. | $232.12 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Mirati Therapeutics, INC. | $143.93 | 2023 | Krazati |
| Adaptive Biotechnologies Corporation | $139.00 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $92.25 | 2023-2024 | Enhertu, Injectafer |
| Kite Pharma, INC. | $87.50 | 2023 | Yescarta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $79.88 | 2024-2025 | Xospata, Vyloy |
| Glaxosmithkline, LLC. | $69.71 | 2023-2025 | Ojjaara, Blenrep |
| Celgene Corporation | $50.14 | 2023-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $47.73 | 2024-2025 | |
| Seagen INC. | $41.60 | 2022-2023 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $40.35 | 2023-2025 | Libtayo |
| Genmab U.S., INC. | $33.16 | 2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $32.46 | 2024 | Tazverik, Onivyde |
| Merck Sharp & Dohme LLC | $30.65 | 2023-2024 | Keytruda |
| Genentech USA, INC. | $28.93 | 2022-2023 | Tecentriq |
| Amgen INC. | $24.61 | 2022 | |
| Gilead Sciences, INC. | $23.65 | 2023 | Trodelvy |
| Incyte Corporation | $21.47 | 2025 | Monjuvi |
| Genzyme Corporation | $21.16 | 2025 | |
| Geron Corporation | $20.44 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2025 | Fruzaqla |
| Eisai INC. | $15.76 | 2025 | |
| Intuitive Surgical, INC. | $13.25 | 2023 | Da Vinci Surgical System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Scheckel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.